Please Wait a Moment
X

Articles

02Oct

Update on the Ortho Conversion

02 Oct, 2020 | Return|

At CTS, we understand the impact converting to the Ortho viral marker platform has on your operations. As we get closer to our implementation date of January 11, 2021 we are committed to providing you information as it becomes available.

Package inserts for the new assays are now available. You can review them on the Communications page by clicking this link: Communications

Related

Spotlight on CTS AABB Annual Meeting Abstract Posters

CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...

Read More >

Shipping conditions for Monolisa anti-HBs EIA

After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...

Read More >

VP, Scientific Affairs Dr. Marion Lanteri Speaks at Symposium on Alternatives to Donation Deferral

As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...

Read More >

FDA announces withdrawal of Guidance for ZIKV Testing

We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...

Read More >

FDA Releases ZIKV Guidance and Grifols ZIKV Assay Licensed- 1st Update

This is the first update to the original CTS communication distributed on July 6th. As previously co...

Read More >

CTS implements Ortho VIP Viral Marker Testing Platform

On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...

Read More >